Universal Beteiligungs und Servicegesellschaft mbH Acquires New Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 122,153 shares of the company's stock, valued at approximately $2,844,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.24% of Spyre Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of SYRE. GF Fund Management CO. LTD. purchased a new position in shares of Spyre Therapeutics during the fourth quarter valued at about $29,000. Huntington National Bank purchased a new stake in Spyre Therapeutics in the fourth quarter worth about $34,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Spyre Therapeutics in the fourth quarter worth about $46,000. KLP Kapitalforvaltning AS purchased a new stake in Spyre Therapeutics in the fourth quarter worth about $182,000. Finally, Tower Research Capital LLC TRC grew its holdings in Spyre Therapeutics by 1,548.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,574 shares of the company's stock worth $200,000 after purchasing an additional 8,054 shares during the period. Hedge funds and other institutional investors own 80.39% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on SYRE. Wedbush restated an "outperform" rating and issued a $65.00 price objective on shares of Spyre Therapeutics in a report on Monday, May 5th. Leerink Partners began coverage on shares of Spyre Therapeutics in a report on Tuesday, April 8th. They issued an "outperform" rating and a $45.00 price objective on the stock. Wolfe Research began coverage on shares of Spyre Therapeutics in a report on Tuesday, March 18th. They issued an "outperform" rating and a $27.00 price objective on the stock. The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, February 18th. Finally, Leerink Partnrs upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a research note on Tuesday, April 8th. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $53.40.

Spyre Therapeutics Price Performance

NASDAQ SYRE traded up $0.35 during trading hours on Friday, hitting $16.97. The company's stock had a trading volume of 309,214 shares, compared to its average volume of 615,761. Spyre Therapeutics, Inc. has a 12 month low of $10.91 and a 12 month high of $40.26. The company's 50 day simple moving average is $14.23 and its two-hundred day simple moving average is $19.55. The company has a market cap of $1.02 billion, a P/E ratio of -2.27 and a beta of 2.78.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.02. As a group, research analysts predict that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current fiscal year.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).